文献速递皮肤肿瘤

德国人群皮肤癌筛查与黑色素瘤死亡率的关系

Population Skin Cancer Screening and Melanoma Mortality Rates.
PubMed 文献 · JAMA Dermatol · 2026-01-01

该生态学比较有效性研究比较2009至2022年德国与9个无人群筛查邻国的黑色素瘤年龄标化死亡率趋势。德国筛查覆盖35岁以上人群、每2年一次视诊、2年参与率约32%;

要点

  • 德国筛查未显示黑色素瘤死亡率获益,结果与既往研究一致
  • 2年参与率约32%,应查明项目表现不佳的原因以支持决策

核心结论

  • 德国人群皮肤癌筛查项目与黑色素瘤死亡率降低无显著关联,与既往未能显示死亡率获益的研究一致。
  • 为对该项目的未来作出有依据的决策,应调查其表现不佳的原因。

研究设计与样本

  • 基于官方死因统计的人群生态学比较有效性研究,比较2009至2022年德国与无人群筛查邻国的黑色素瘤死亡率趋势。
  • 分析覆盖德国15个联邦州与9个邻国的总人口,德国石勒苏益格-荷尔斯泰因州因2003至2004年试点项目的潜在持续效应被排除。

主要发现

  • 2009至2022年各纳入地区年龄标化黑色素瘤死亡率均下降。
  • 德国APC范围为-3.8%(95%CI,-5.5%至-2.2%)至-0.1%(95%CI,-1.7%至1.5%)。
  • 对照地区死亡率每年下降-3.8%(95%CI,-4.9%至-2.7%)至-1.0%(95%CI,-1.9%至-0.2%)。

关键数值与推荐

  • 德国筛查项目覆盖35岁及以上男女,每2年一次视诊皮肤检查,不论个体皮肤癌风险。
  • 2年参与率估计约32%。

临床怎么用

  • 该研究提示不应假定人群视诊筛查必然降低黑色素瘤死亡率;对筛查项目的评估与决策应参考此类人群水平证据。
  • 项目优化前需查明参与率与效果不足的原因。

局限性

  • 为生态学比较有效性研究,非个体随机对照设计。
  • 排除石勒苏益格-荷尔斯泰因州,可能影响德国整体代表性。
  • 观察期至2022年,筛查的长期效应可能尚未完全显现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In Germany, a population-based skin cancer screening (SCS) program was implemented in 2008. The benefit of the intervention is unclear. OBJECTIVE: To determine whether the German SCS program was associated with reduced melanoma mortality. DESIGN, SETTING, AND PARTICIPANTS: This population-based, ecological comparative effectiveness study compared trends in melanoma mortality from 2009 to 2022 in Germany with those in neighboring countries without population-based SCS using data on melanoma mortality from the official cause-of-death statistics. The total populations of 15 federal states of Germany and 9 neighboring countries were examined. The German federal state of Schleswig-Holstein was excluded from the analysis due to a potential lasting effect of a preceding pilot project, conducted in 2003 and 2004. Data were analyzed from November 7, 2025, to February 11, 2026. EXPOSURE: The German SCS program entitles men and women aged 35 years and older to a visual skin examination every 2 years, regardless of their individual skin cancer risk. The 2-year participation rate was estimated at approximately 32%. MAIN OUTCOMES AND MEASURES: Pooled estimates of annual percentage changes (APCs) in age-standardized melanoma mortality rates in German and non-German control regions were calculated using a random-effects model. RESULTS: Data include a mean of 79.1 million inhabitants in Germany and 164.8 million inhabitants in 9 neighboring countries. Between 2009 and 2022, age-standardized melanoma mortality rates decreased in each included region. In Germany, APCs ranged from -3.8% (95% CI, -5.5% to -2.2%) to -0.1% (95% CI, -1.7% to 1.5%). In the control regions, mortality rates decreased between -3.8% (95% CI, -4.9% to -2.7%) and -1.0% (95% CI, -1.9% to -0.2%) per year. Pooled APC estimates are -1.8% (95% CI, -2.3% to -1.4%) for Germany and -2.2% (95% CI, -2.8% to -1.6%) for the non-German control regions; the difference was not statistically significant (P = .42). CONCLUSIONS AND RELEVANCE: The findings of this ecological study are in line with previous studies that failed to show a melanoma mortality benefit associated with the German SCS program. To enable a well-founded decision on the future of the program, the causes of its poor performance should be investigated.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Hübner J, Schumann L, Eisemann N, et al. Population Skin Cancer Screening and Melanoma Mortality Rates. JAMA Dermatol. 2026. PMID: 42268621. doi:10.1001/jamadermatol.2026.1527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。